MPC Member Publications

This database contains a listing of population studies publications written by MPC Members. Anyone can add a publication by an MPC student, faculty, or staff member to this database; new citations will be reviewed and approved by MPC administrators.

Full Citation

Title: Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC)

Citation Type: Journal Article

Publication Year: 2016

ISSN: 1055-9965

DOI: 10.1158/1055-9965.EPI-15-0849

PMID: 26908438

Abstract: BACKGROUND Serum β-2 microglobulin (B2M), a major histocompatibility complex class I molecule that is a biomarker of kidney filtration and increased cell turnover, is elevated at the time of diagnosis in hematological and some solid cancers. However, serum B2M was not examined prospectively as a marker for cancer risk. We hypothesized that in a population without a prior cancer diagnosis, serum B2M is associated with risk of cancer (n = 2,436), including colorectal (n = 255), lung (n = 298), breast (n = 424), and prostate (n = 524) cancers, and hematological (n = 176) malignancies. METHODS The analytical cohort (n = 12,300) was followed for incident cancers from 1990 through 2006. B2M (range, 0.9-57.8 mg/L) was measured in stored serum collected in 1990-1992. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals for cancer incidence and mortality in relation to quartiles of B2M. RESULTS Adjusting for age, sex, race, center, education, body mass index, smoking, aspirin, and hormone therapy (in women) and comparing highest to lowest B2M quartiles, HRs were 1.25 (1.06-1.47; Ptrend = 0.002) for total cancer risk and 2.21 (1.32-3.70; Ptrend=0.001) for colorectal cancer risk, with similar HRs for colon and rectal cancers. These associations remained after adjustment for an inflammatory biomarker, C-reactive protein, and after excluding the first three years of follow-up. Significant associations were also observed for mortality from total, lung, and hematological cancers. CONCLUSIONS These findings provide the first evidence that higher serum B2M is associated with increased colorectal cancer risk. IMPACT This study supports B2M as a potential biomarker for colorectal cancer risk. Cancer Epidemiol Biomarkers Prev; 25(4); 657-64. ©2016 AACR.

Url: http://www.ncbi.nlm.nih.gov/pubmed/26908438

Url: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4873421

Url: http://cebp.aacrjournals.org/cgi/doi/10.1158/1055-9965.EPI-15-0849

User Submitted?: No

Authors: Prizment, Anna E; Linabery, Amy M.; Lutsey, Pamela L.; Selvin, Elizabeth; Nelson, Heather H.; Folsom, Aaron R; Church, Timothy R; Drake, C. G.; Platz, E. A.; Joshu, C.

Periodical (Full): Cancer Epidemiology Biomarkers & Prevention

Issue: 4

Volume: 25

Pages: 657-664

Countries:

IPUMS NHGIS NAPP IHIS ATUS Terrapop